<?xml version="1.0" encoding="UTF-8"?>
<p id="Par2">Human metapneumovirus (hMPV), first identified in 2001, is a major viral respiratory pathogen that worldwide reported
 <sup>
  <xref ref-type="bibr" rid="CR1">1</xref>
 </sup>. It is estimated that 4–16% of acute respiratory tract infections are caused by HMPV
 <sup>
  <xref ref-type="bibr" rid="CR2">2</xref>,
  <xref ref-type="bibr" rid="CR3">3</xref>
 </sup>. Retrospective serologic studies demonstrated 100% seroprevalence of hMPV antibodies among children ≤5 years of age
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>
 </sup>. Moreover, reinfection can occur throughout life
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>,
  <xref ref-type="bibr" rid="CR6">6</xref>
 </sup>, further contributing to the prevalence of hMPV. Clinical features of HMPV infection are similar to those associated with human respiratory syncytial virus infection, ranging from mild respiratory illnesses to severe bronchiolitis and pneumonia
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>,
  <xref ref-type="bibr" rid="CR7">7</xref>
 </sup>. Children under five years, aged adults, and patients with underlying diseases are more likely to develop severe diseases
 <sup>
  <xref ref-type="bibr" rid="CR8">8</xref>
 </sup>.
</p>
